A Phase I, Open-label, Randomised, 3-way Crossover Study to Demonstrate Bioequivalence of a Single Oral Dose of Naproxen Administered as VIMOVO Manufactured at AstraZeneca AB Compared to That of VIMOVO Manufactured by Patheon Pharmaceuticals and a Marketed Enteric-coated Naproxen Formulation (Manufactured by Roche) in Healthy Volunteers.

Trial Profile

A Phase I, Open-label, Randomised, 3-way Crossover Study to Demonstrate Bioequivalence of a Single Oral Dose of Naproxen Administered as VIMOVO Manufactured at AstraZeneca AB Compared to That of VIMOVO Manufactured by Patheon Pharmaceuticals and a Marketed Enteric-coated Naproxen Formulation (Manufactured by Roche) in Healthy Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Oct 2011

At a glance

  • Drugs Esomeprazole/naproxen (Primary) ; Naproxen
  • Indications Arthritis; Pain
  • Focus Pharmacokinetics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 17 Oct 2011 Actual end date (Oct 2011) added as reported by ClinicalTrials.gov.
    • 17 Oct 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 22 Sep 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top